Sunitinib in metastatic renal cell carcinoma: clinical outcomes across risk groups in a Turkish Oncology Group Kidney Cancer Consortium

Le résumé fourni par la source

Renal cell carcinoma (RCC) is responsible for an estimated 434,419 new cases and 155,702 deaths, which amounts to 2.2% of all new cancer globally [1].Despite the advent of new combination therapies, the 3-year overall survival (OS) in metastatic RCC (mRCC) remains around 60% [2-4].To stratify the patients according to their prognosis, the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) model and the Memorial Sloan Kettering Cancer Center (MSKCC) model, are well developed and used before the initiation of the treatment.Sunitinib was the standard of care after showing superiority over interferon alfa in mRCC until immunotherapy (IO) combinations gained approval [5].While IO and antivascular endothelial growth factor (VEGF) tyrosine kinase inhibitor (TKI) combinations are recommended first-line, they have not shown a significant OS benefit in patients with IMDC favorable risk and remain costly, limiting access in resource-constrained settings.This study evaluates clinical outcomes of mRCC patients treated with first-line sunitinib and aims to identify factors impacting these outcomes.We conducted a retrospective cohort study using data from the Turkish Kidney Cancer Consortium (TKCC) database.The study included patients aged 18 and older diagnosed with mRCC and treated with sunitinib as a first-line therapy.The primary objectives were to evaluate time to treatment failure (TTF) across risk groups and identify factors affecting TTF.Secondary objectives included assessing OS by risk group, factors affecting OS,

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.